Cary Street Partners Investment Advisory’s Quest Diagnostics DGX Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Sell	1,059 -117	-10%	-$23K	0.05%	349
2026 Q1	$230K	Sell	1,176 -224	-16%	-$43.5K	0.06%	324
2025 Q4	$243K	Sell	1,400 -129	-8%	-$23.5K	0.07%	290
2025 Q3	$291K	Buy	1,529 +452	+42%	+$80.2K	0.12%	189
2025 Q2	$193K	Buy	1,077 +40	+4%	+$6.95K	0.09%	247
2025 Q1	$175K	Buy	1,037 +839	+424%	+$138K	0.1%	234
2024 Q4	$29.9K	Sell	198 -2,179	-92%	-$339K	0.02%	370
2024 Q3	$369K	Sell	2,377 -630	-21%	-$94.1K	0.01%	566
2024 Q2	$412K	Buy	+3,007	New	+$412K	0.02%	516
2023 Q4	–	Sell	-297	Closed	-$36.2K	–	899
2023 Q3	$36.2K	Hold	297	–	–	﹤0.01%	953
2023 Q2	$41.7K	Sell	297 -4	-1%	-$551	﹤0.01%	861
2023 Q1	$42.6K	Hold	301	–	–	﹤0.01%	787
2022 Q4	$47.1K	Buy	+301	New	+$43.3K	﹤0.01%	763
2020 Q4	–	Sell	-47	Closed	-$5K	–	471
2020 Q3	$5K	Buy	+47	New	+$5.55K	﹤0.01%	834

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Cary Street Partners Investment Advisory's DGX Position: Q2 2026 in Review

Cary Street Partners Investment Advisory reduced its Quest Diagnostics (DGX) stake by 9.9% in Q2 2026, selling an estimated $23K and leaving 1,059 shares worth $224K. The position accounts for 0.05% of the portfolio, ranked #349.

Cary Street Partners Investment Advisory first reported a position in DGX in Q3 2020 and has held it in 14 quarters since. The position peaked at $412K in Q2 2024. 765 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Cary Street Partners Investment Advisory held 1,059 shares of Quest Diagnostics worth $224K as of Q2 2026.
Cary Street Partners Investment Advisory sold 117 Quest Diagnostics shares in Q2 2026, an estimated $23K.
Quest Diagnostics made up 0.05% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #349 holding.
Cary Street Partners Investment Advisory first reported a position in Quest Diagnostics in Q3 2020 and has held it in 14 quarters since.
Cary Street Partners Investment Advisory's Quest Diagnostics position peaked at $412K in Q2 2024.
765 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.